What are the treatment options for NTRK gene fusion positive non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

For patients who are NTRK gene fusion positive, the following agents are used:

  • Larotrectinib (Vitrakvi)(preferred)
  • Entrectinib (Rozlytrek)(preferred)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!